Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00097799
First received: November 30, 2004
Last updated: October 30, 2013
Last verified: October 2013

November 30, 2004
October 30, 2013
December 2004
August 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00097799 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)

This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.

Not Provided
Expanded Access
Not Provided
Not Provided
HIV Infections
  • Drug: Tipranavir
    500 mg twice daily
  • Drug: Ritonavir
    200 mg twice daily
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Not Provided
Not Provided
August 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Not Provided
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00097799
1182.70
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP